Tumor necrosis factor receptor-associated factor regulation of nuclear factor κB and mitogen-activated protein kinase pathways
Tumor necrosis factor receptor (TNFR)-associated factors (TRAFs) are a family of structurally
related proteins that transduces signals from members of TNFR superfamily and various …
related proteins that transduces signals from members of TNFR superfamily and various …
Fueling the fire: inflammatory forms of cell death and implications for cancer immunotherapy
SR Rosenbaum, NA Wilski, AE Aplin - Cancer discovery, 2021 - AACR
Unleashing the immune system with immune checkpoint inhibitors (ICI) has significantly
improved overall survival for subsets of patients with stage III/IV cancer. However, many …
improved overall survival for subsets of patients with stage III/IV cancer. However, many …
Therapeutically increasing MHC-I expression potentiates immune checkpoint blockade
Immune checkpoint blockade (ICB) therapy revolutionized cancer treatment, but many
patients with impaired MHC-I expression remain refractory. Here, we combined FACS-based …
patients with impaired MHC-I expression remain refractory. Here, we combined FACS-based …
Tumor immune evasion arises through loss of TNF sensitivity
Immunotherapy has revolutionized outcomes for cancer patients, but the mechanisms of
resistance remain poorly defined. We used a series of whole-genome clustered regularly …
resistance remain poorly defined. We used a series of whole-genome clustered regularly …
Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity
O Dufva, J Koski, P Maliniemi, A Ianevski… - Blood, The Journal …, 2020 - ashpublications.org
Chimeric antigen receptor (CAR) T-cell therapy has proven effective in relapsed and
refractory B-cell malignancies, but resistance and relapses still occur. Better understanding …
refractory B-cell malignancies, but resistance and relapses still occur. Better understanding …
4-1BB costimulation promotes CAR T cell survival through noncanonical NF-κB signaling
Clinical response to chimeric antigen receptor (CAR) T cell therapy is correlated with CAR T
cell persistence, especially for CAR T cells that target CD19+ hematologic malignancies. 4 …
cell persistence, especially for CAR T cells that target CD19+ hematologic malignancies. 4 …
Augmenting immunotherapy impact by lowering tumor TNF cytotoxicity threshold
DW Vredevoogd, T Kuilman, MA Ligtenberg… - Cell, 2019 - cell.com
New opportunities are needed to increase immune checkpoint blockade (ICB) benefit.
Whereas the interferon (IFN) γ pathway harbors both ICB resistance factors and therapeutic …
Whereas the interferon (IFN) γ pathway harbors both ICB resistance factors and therapeutic …
A review of the current impact of inhibitors of apoptosis proteins and their repression in cancer
Simple Summary The Inhibitor of Apoptosis (IAP) family of proteins has emerged as a
potential pharmacological target in cancer. Abnormal expression of IAPs can lead to …
potential pharmacological target in cancer. Abnormal expression of IAPs can lead to …
Cancer immunotherapy: beyond checkpoint blockade
M Dougan, G Dranoff, SK Dougan - Annual Review of Cancer …, 2019 - annualreviews.org
Blocking antibodies to the immune checkpoint receptors or their ligands have revolutionized
the treatment of diverse malignancies. Many tumors are recognized by adaptive immunity …
the treatment of diverse malignancies. Many tumors are recognized by adaptive immunity …
A systematic review on poly (I: C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy
J De Waele, T Verhezen, S van der Heijden… - Journal of Experimental …, 2021 - Springer
Immunotherapy is currently under intensive investigation as a potential breakthrough
treatment option for glioblastoma. Given the anatomical and immunological complexities …
treatment option for glioblastoma. Given the anatomical and immunological complexities …